WillItSurvive
Medical technology and health companies · United States

Fulgent Genetics

fulgentgenetics.com ↗

Genetic testing and diagnostics lab running COVID-era cash into oncology and pathology.

Losing its protection
Assessed 31 July 2026 · Evidence as of 31 July 2026
The structural protection is eroding.
On the recordSince 31 July 2026 · Checkable from Oct/Nov 2026 · Every call on the record Checkpoint: Q3 2026 earnings print on billing fix, collections recovery, and anatomic pathology guidance
The call

Fulgent is stitching acquired pathology revenue onto a shrinking core testing business while bigger labs absorb its customers.

Fulgent Genetics runs genetic testing labs that analyze DNA samples for diseases and health risks. Big competitors like Labcorp and Quest can easily copy what Fulgent does since genetic testing itself is not hard to replicate, and some customers are already building their own labs instead of paying Fulgent. The company has had billing problems and faces potential lawsuits, which is why investors are betting the whole business is worth nothing and only the cash on hand has value. If Fulgent can fix its billing system and collect money properly over the next year, and if its pathology division starts hitting financial targets, the picture could improve, but right now the market is betting against it.

Why
01
AI pressure: None apparent. AI aids test interpretation industry-wide but no AI lab is taking Fulgent's testing volume directly. Could AI do the core job? Only partly.
02
Bigger players: Labcorp and Quest Diagnostics. A major customer already moved volume in-house, and Labcorp's 160M+ test scale lets it undercut Fulgent on price and reach. Could a giant copy it? Yes, easily.
03
What protects it. CLIA/CAP licensure and payer contracts keep new entrants out, but they protect the whole lab industry, not Fulgent specifically.
What would change this call
Q3 2026 earnings (Oct/Nov 2026) show anatomic pathology revenue versus the guided $146-150M range. Hitting the range would show stabilizing demand; missing it would show continued customer loss.
A securities-fraud class action against Fulgent is formally filed in court. Would show billing and disclosure problems are severe enough to draw litigation, denting trust.
Fulgent announces a third guidance cut or names another lost anchor customer in 2026. Would confirm accelerating customer defection to rivals rather than a one-time issue.
Key numbers
  • Q2 2026 net loss $29.5 million (2026-07-30)
  • FY2026 guidance cut to $330-340M from $350M (2026-07-30)
  • Q1 2026 revenue fell 3.6% YoY to $71.1M (2026-05-02)
Named risks
  • Multiple law firms investigating securities fraud tied to Feb 27 2026 guidance cut; no suit filed yet. Severity: high
  • Customer concentration: major client already insourced testing volume, hurting revenue. Severity: high
  • Guidance cut twice in 2026 amid billing-system transition and collection problems. Severity: high
  • Integration risk from $56.4M Bako/StrataDx acquisition closed March 2026. Severity: medium
  • Clinical pipeline (FID-007, FID-022) outcomes remain unproven catalysts. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
Labcorplosing toLabcorp processes 160M+ tests/year vs Fulgent's $322.7M FY2025 revenue, as of 2026-07-30
Quest Diagnosticslosing toScaled incumbent shares same CLIA licensure with no structural barrier to entering Fulgent's niche
NateracontestingSpecialized genomics peer competing directly in hereditary and NIPT testing segments
Guardant HealthcontestingNamed peer in oncology diagnostics per market comparison reports as of 2026
Myriad GeneticscontestingOverlapping hereditary cancer test menu identified as direct competitor
Questions people ask
What is Fulgent Genetics' biggest risk?
The biggest risk is hospital systems building their own in-house sequencing on Illumina and Thermo Fisher platforms, which pulls test volume directly away from Fulgent's lab. Its largest customer completed this in-house migration in Q1 2026, and that shift contributed to Q1 2026 revenue falling 14.6% sequentially to $71.1M. Within its 12-company diagnostics cohort, Fulgent ranks 9th, underscoring how exposed it is to this trend.
Is Fulgent Genetics in financial trouble?
Not immediately, but the numbers are mixed. FY2025 revenue was $322.7M with a net loss of $(60.5)M, and Q1 2026 revenue dropped to $71.1M from the prior quarter after its biggest customer's in-house migration. The company still holds $604.7M in cash as of 2026-03-31, which is more than its entire market cap of $565M, giving it a buffer to fund a pivot rather than an immediate crisis.
Who are Fulgent Genetics' biggest competitors?
Within its 12-company diagnostics cohort, Fulgent ranks 9th, behind Labcorp's network of more than 2,000 centers, Quest Diagnostics' payer relationships, and Natera's stronger reproductive and oncology-monitoring franchises. Fulgent's main point of difference is its broad menu of over 18,000 tests, though our July 2026 assessment found little protecting that advantage from larger, better-resourced rivals.
Is Fulgent Genetics at risk from AI?
Partly. AI-driven interpretation software like Illumina's DRAGEN, paired with in-house sequencers, lets hospitals read routine genomic results themselves instead of sending samples to outside labs like Fulgent. This is listed as a building threat rather than one that has fully played out, and it compounds the pressure already visible from Fulgent's largest customer completing its own in-house sequencing migration in Q1 2026, which coincided with a sequential revenue drop to $71.1M.
What protects Fulgent Genetics from losing more business?
Fulgent's shield includes CLIA/CAP lab accreditation, physician-signed interpretation, and established payer billing codes, plus over $600M in cash as of 2026-07-22 to fund a specialty pivot. These are real but limited protections; our July 2026 assessment found little else shielding the business from further customer losses, as shown by its largest customer's completed in-house migration in Q1 2026.
What should I watch to see if Fulgent Genetics is turning around?
Two dated checkpoints matter. By 2027-02, watch whether full-year 2026 revenue lands at or below the $350M guidance amid continued customer in-house migration, and by 2026-12, watch whether a securities class-action lawsuit is filed tied to the February 27, 2026 stock drop. The Q2 2026 earnings report on July 30, 2026, the first full quarter after the Bako/StrataDx integration and the largest-customer loss, is also a near-term signal to check.
Timeline
  • 2026-07-30Q2 2026 revenue $85.4M reported; FY2026 guidance cut to $330-340M
  • 2026-06-01Updated FID-007 Phase II data presented at ASCO in Head and Neck Cancer track
  • 2026-05-01Q1 2026 results released; FY2026 guidance reiterated at ~$350M
  • 2026-03-17Kirby McInerney announces securities-fraud investigation into Fulgent
  • 2026-03Bako Diagnostics and StrataDx acquisition closes for $56.4M adjusted price
  • 2026-02-28Q4 2025 call discloses Eziopath platform reached 100% digital pathology conversion
  • 2026-02-27Guidance cut disclosed; stock falls approximately 38% in a single day
  • 2016-09-29Fulgent Genetics IPO on Nasdaq under ticker FLGT
Head to head
Fulgent Genetics vs Myriad Genetics
Revision history
31 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
NeuralinkKingmed DiagnosticsMeinian Onehealth
More in Medical technology and health companies →
Sources